Prottay Dutta

Dr. Prottay Dutta

orcid

Research Focus & Metrics

Academic Career Length

1Year (2026-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 March 2024 in Journal of Drug Delivery and Therapeutics
Verified
Journal Article
Open access
PDF file
RPRahul Pal
Rahul Pal
PPPrachi Pandey
Prachi Pandey
MKManju Koli
Manju Koli
KSKhushi Srivastava
Khushi Srivastava
VTVaisanavi Tiwari
Vaisanavi Tiwari
PDProttay Dutta
Prottay Dutta
This comprehensive review aims to explore the future potential of nasopulmonary drug delivery systems for the administration of drugs through the nasal route. Nasal drug delivery has gained significant attention due to its numerous advantages, including rapid absorption, avoidance of first-pass metabolism, and non-invasive administration. This review provides an overview of the nasal anatomy and physiology, highlighting the factors influencing drug absorption and bioavailability. Additionally, it discusses the various types of nasopulmonary drug delivery systems, such as nasal sprays, powders, and gels, along with their advantages and limitations. Furthermore, the review delves into the challenges associated with nasal drug delivery, including mucociliary clearance, nasal irritation, and formulation issues. The potential applications of nasopulmonary drug delivery systems in the treatment of various diseases, such as allergies, respiratory disorders, and systemic conditions, are also discussed. Finally, the review concludes with an outlook on the future prospects of nasopulmonary drug delivery systems, emphasising the need for further research and development to optimise their efficacy and safety. Keywords: nasal pulmonary; nasal spray; nasal mucosa; gels; drops; nasal approaches; nasal route; nasal delivery.

13 November 2025 in Current Nanomedicine
Verified
Journal Article
Closed access
MKManju Koli
Manju Koli
TSTapaskumar Mukeshkumar Shah
Tapaskumar Mukeshkumar Shah
PDProttay Dutta
Prottay Dutta
NPNeetu Patel
Neetu Patel
APAbhay Kumar Patel
Abhay Kumar Patel
RPRahul Pal
Rahul Pal
Niosomes (Niosomes), as Non-Ionic Surfactant (NIOs)-based vesicles, have emerged as versatile nanocarriers in the targeted delivery of drugs due to their biocompatibility, chemical stability, and ability to encapsulate both hydrophilic and lipophilic drugs. Their utility has gained significant traction in addressing challenges associated with conventional therapies, for chronic and resistant diseases, Tuberculosis (TB), and cancer. This review critically evaluates the role of NIOs in the formulation of Niosomes, emphasizing their influence on clinical efficacy, pharma-cokinetics, and targeted drug delivery. It also explores the emerging patent landscape and transla-tional potential of Niosomes systems in TB and oncology. A comprehensive literature and patent database search was conducted using PubMed, Google Scholar, ScienceDirect, Scopus, Elsevier, SpringerLink, and ClinicalTrials.gov, as well as Google Patents, USPTO, and WIPO, covering publications and patents from 20202025 onwards. The relevant studies, clinical trials, and granted patents involving Niosomes formulations with NIOs were systematically analyzed for their for-mulation design, therapeutic outcomes, and disease-specific applications. The study showed a no-table rise in research and patents on Niosomes drug delivery using NIOs categories. In TB, these systems enhanced Bioavailability (BA), sustained drug release, and targeted macrophages. In cancer therapy, they enabled controlled release, minimized side effects, and improved tumor tar-geting. The recent patents highlight advances in combination therapies, responsive systems, and ligand-based targeting, reflecting a trend toward personalized medicine. NIOs play a critical role in modulating the performance of Niosomes drug carriers. Their strategic application in TB and oncology represents a promising avenue for improving therapeutic outcomes. Continued research and innovation in this field, as reflected by patent trends, highlight the translational potential of NIO-based Niosomes formulations toward clinical use.

13 June 2026 in Journal of Microencapsulation
Verified
Journal Article
Closed access
RPRahul Pal
Rahul Pal
Binita GhoshBinita Ghosh
Binita Ghosh
PDProttay Dutta
Prottay Dutta
TSTapaskumar Mukeshkumar Shah
Tapaskumar Mukeshkumar Shah
ASAkashdeep Singh
Akashdeep Singh
Tuberculosis (TB) persists as a global threat, worsened by MDR/XDR strains. Conventional therapies suffer from poor compliance, toxicity, and targeting. Nanotechnology-driven systems enhance bioavailability, targeting, and treatment efficacy. This review explores recent advances in novel drug delivery carriers for TB, emphasising clinical trial progress and global patent trends. It highlights key innovations, emerging patterns, and existing translational gaps in the field. A thorough literature search (March 1, 2020-March 1, 2025) across major databases (PubMed, Scopus, Google Scholar, ClinicalTrials.gov, Google Patents) is conducted to compile recent data on nano-formulations for TB treatment. The review highlights key Novel drug delivery carriers (NDCs) and others-as promising TB treatments. Patent trends show growing global interest, particularly from countries such as India, the United States, and China. NDCs offer transformative potential for TB treatment, addressing traditional therapy limits. Advancing research and patents show growing adoption, clinical success studies and scalable production.

9 September 2025
Verified
Book
Open access
PDF file
RPRahul Pal
Rahul Pal
Binita GhoshBinita Ghosh
Binita Ghosh
MKManju Koli
Manju Koli
PDProttay Dutta
Prottay Dutta
It is with immense pride and gratitude that I present this edited volume, “Next-Gen Nanomedicine for Breast Cancer: From Bench to Bedside and Beyond.” This book brings together the collective efforts of researchers, clinicians, and academicians working at the interface of nanotechnology and oncology, aiming to illuminate the path toward more effective, targeted, and patient-friendly therapeutic strategies for breast cancer. The vision behind this book has always been to bridge the gap between fundamental research and clinical application. Nanomedicine has emerged as one of the most promising frontiers in modern science, and its role in revolutionizing breast cancer management cannot be overstated. Each chapter reflects the dedication and insight of experts in the field, offering readers not only cutting-edge scientific knowledge but also a glimpse into the future of personalized medicine.

10 March 2026 in Current Nanomedicine
Verified
Journal Article
Closed access
PDF file
AKAmar Kumar
Amar Kumar
SSSubhashree Sahoo
Subhashree Sahoo
RMRakhi Mishra
Rakhi Mishra
PDProttay Dutta
Prottay Dutta
Binita GhoshBinita Ghosh
Binita Ghosh
RPRahul Pal
Rahul Pal
Objective: This review aims to critically evaluate lipidic nanocarriers (liposomes) as effective and targeted delivery systems in cosmeceuticals, with an emphasis on their therapeutic efficacy in dermatological and cosmetic applications. Background: This review aims to critically evaluate lipidic nanocarriers (liposomes) as effective and targeted delivery systems in cosmeceuticals, with an emphasis on their therapeutic efficacy in dermatological and cosmetic applications. Methodology: An extensive literature review was conducted using PubMed/Medline/PMC, Scopus, ScienceDirect, Google Scholar, Google Patents, and ClinicalTrials.gov.in databases. The selected studies focused on L-Omes design, preparation methods, characterization parameters, skin penetration potential, and in vitro/in vivo efficacy within the time 1 May 2015-1 May 2025 (10 years). Recently, commercial cosmeceutical products incorporating L-Omes, along with their clinical trial data and patent developments, have also been highlighted. Results: L-Omes significantly improve the delivery of active agents in cosmeceutical formulations, enhancing skin absorption, prolonging retention, and minimizing systemic toxicity. Vitamins, peptides, antioxidants, and herbal extracts encapsulated with L-Omes showed superior therapeutic efficacy in treating hyperpigmentation, wrinkles, dryness, and acne. Conclusion: L-Omes represent a revolutionary step in the cosmeceutical industry due to their exceptional targeting potential, safety profile, and controlled release properties. L-Omes are ideal carriers for advanced dermatological and cosmetic therapies due to their ability to encapsulate diverse bioactives. Ongoing L-Omes nanotechnology innovations hold promise for personalized and more effective skincare solutions.

16 February 2026
Verified
Book Chapter
Closed access
SVSakshi Verma
Sakshi Verma
PDProttay Dutta
Prottay Dutta
PDPran Kishore Deb
Pran Kishore Deb
RGRatna Ghosh
Ratna Ghosh
Katharigatta VenugopalaKatharigatta Venugopala
Katharigatta Venugopala
Manik GhoshManik Ghosh
Manik Ghosh